SCHEMBL2394698

SCHEMBL2394698

CC(=O)Cc1ccc(S(C)(=O)=O)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
ABCB11 O95342 1/20 0.40
KCNH2 Q12809 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
RXRA P19793 2/20 0.37
RXRB P28702 2/20 0.37
RXRG P48443 2/20 0.37
ALDH1A1 P00352 1/20 0.35
CCR2 P41597 1/20 0.34
CYP2C19 P33261 1/20 0.34
GRIA2 P42262 1/20 0.34
DDR1 Q08345 1/20 0.34
POLB P06746 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
KIF11 P52732 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059397 0.81 PTGDR2 (0.46) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL48565 0.80 GPR119 (0.46) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1146258 0.80 PTGDR2 (0.42) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1940171 0.80 PTGDR2 (0.42) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL250696 0.78 PTGDR2 (0.50) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
Hydrochloric Acid SCHEMBL249100 0.78 PTGDR2 (0.42) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6213644 0.78 P2RX7 (0.47)
SCHEMBL48582 0.76 CYP4F2 (0.37) PTGDR2PIK3CAKCNH2GPR119ALDH1A1
SCHEMBL10278682 0.76 PTGDR2 (0.40) PTGDR2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL12672499 0.74 KIF11 (0.51) RXRARXRBRXRGKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 PTGDR2 1628/4885PIK3CD 42/4885PIK3CA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.